MARION, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Greene Concepts, Inc. (OTC: INKW) shares an open letter to shareholders and investors; the “op-ed” below was penned by Karen Howard. As most know, Karen Howard is also the CEO of Greene Concepts Inc. The Company wishes to distribute the op-ed piece for informational and sharing purposes as it is such insightful piece of writing. The piece gives recognition that government and appointments within governmental agencies can affect business as well as the markets in which they operation.
The piece was written and distributed by Karen Howard as follows:
I went on a bit of a dive to see what makes incoming FDA Commissioner Dr. Ned Sharpless tick. Overall, he appears to be a brilliant conventional doctor specializing in cancer with his research directives and major initiatives. He also has an interesting (though not near as unique as it used to be for physicians) entrepreneurial background. It was during his tenure at the University of University of North Carolina Lineberger Comprehensive Cancer Center when he first learned about Small Business Innovation Research (SBIR) grants. He and his colleagues used SBIR funding (from NIAID, NCI and the National Institute of Diabetes and Digestive and Kidney Diseases) to advance research that then enabled venture capital backing for a now publicly traded company doing clinical trials for small cell lung cancer and triple-negative breast cancer. Dr. Sharpless is a founder of both GI Therapeutics, specializing in cancer drugs, and Sapere Bio(formerly Healthspan Diagnostics), a company with the tag line, "Measuring physiologic reserve to improve healthcare. "
Fast forward to his time at the National Cancer Institute and the rationale for his transition to FDA becomes more clear in a blog post from last September entitled, “NCI and FDA Address Common Concerns: A Win–Win for Making Progress against Cancer.” In addition to inter-agency collaboration on the ages-old workforce development and training of scientists to “bridge research and regulatory science,” NCI and FDA have commonality relating the impact of nicotine on tobacco use. NCI, with its large body of research on how decreasing nicotine levels will decrease smoking rates; FDA asserting its intent to reduce nicotine to nonaddictive or minimally addictive levels. Enter stage left, e-cigarettes and the potential for young users to transition to real cigarettes with an increase in cancer rates.
In a review of the NCI 2019 budget created under Dr. Sharpless’ direction you can find the following objectives:
- Increase support for cancer research through research project grants (RPGs)
- Stay true to the vision of the Cancer Moonshot research initiative, funded by Congress in the amount of $400 million
- Prioritize training and supporting early-stage investigators (ESIs) to ensure a robust cancer research workforce pipeline.
End result, NASDAQ BioTech stocks rose with the announcement of the Doctor’s transition to FDA. (Tobacco stocks dipped) The only relationship in writing associating Dr. Sharpless and supplements is the term ‘supplemental funding.’ Conclusion? I sure wouldn’t make any cancer claims. Short of that, I predict business as usual at the FDA. But don’t ask me to define what that means!
About Greene Concepts, Inc. and Mammoth Ventures Inc.
Greene Concepts, Inc. (http://www.greeneconcepts.com) is a publicly traded company and thru its newly acquired wholly-owned subsidiary Mammoth Ventures Inc. has entered into the specialty beverage and bottling business.
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Greene Concepts, Inc.
Investor Relations
info@mammothventuresinc.com